Previous close | 67.11 |
Open | 67.87 |
Bid | 66.90 x 100 |
Ask | 67.28 x 100 |
Day's range | 66.75 - 67.87 |
52-week range | 37.87 - 70.81 |
Volume | |
Avg. volume | 145,387 |
Market cap | 1.404B |
Beta (5Y monthly) | 0.80 |
PE ratio (TTM) | 78.72 |
EPS (TTM) | 0.85 |
Earnings date | 10 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 79.80 |
Moderna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.
BAUDETTE, Minn., May 01, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will participate at two upcoming healthcare conferences in New York City as follows: Capital One 1st Annual Biotech/Biopharma Disruptors Event Date:Tuesday, May 14, 2024 Time:12:15pm ET To schedule a 1x1 meeting with management, please contact kristen.patrick@capitalone.com H.C. Wa
GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales for the full year.